CD274 and non-small cell lung carcinoma: Pembrolizumab monotherapy provides significantly superior ORR, PFS, and OS for patients with NSCLC and PD‐L1 expression of ≥50%,5 although high rates of PD have been reported (>20% regardless of race), with rates reaching 28.7% among French patients6 and 24.2% among Japanese patients.37